1. INTRODUCTION

1.1 Report Description

1.2 Research Methodology

1.3 Stakeholders

2. EXECUTIVE SUMMARY

2.1 Key Findings

2.2 Market Overview

3. MARKET OVERVIEW

3.1 Market Definition

3.1.1 Introduction

3.2 Market Drivers

3.2.1 Global Cancer

3.2.2 Wide range of applications

3.2.3 Increasing investments & funds

3.3 Market Restraints

3.3.1 Lack of Reimbursement plans

3.3.2 Lack of predictive markers

4. GLOBAL MARKETS: SEGMENTATION BY THERAPEUTICS, RESEARCH & DIAGNOSTICS

4.1 Therapeutics

4.1.1 Oncology Conditions

4.1.2 Non-Oncology Indications

4.1.3 Personalized Medicine

4.2 Research & Diagnostics

4.2.1 Gene Regulation Studies

4.2.2 Biomarker Detections

4.2.3 Drug Discovery

5. GLOBAL MARKETS: SEGMENTATION BY GEOGRAPHY

5.1 North America

5.1.1 USA

5.1.2 Canada

5.1.3 Mexico

5.2 Europe

5.2.1 UK

5.2.2 Germany

5.2.3 France

5.2.4 Spain

5.3 APAC

5.3.1 India

5.3.2 China

5.3.3 Japan

5.3.4 South Korea

6. COMPETITVE LANDSCAPE

6.1 Introduction

6.2 Mergers & Acquisitions

6.3 Expansions

6.4 New Product Launch

6.5 Collaborations

7. COMPANY PROFILES

7.1 4SC

7.2 Celgene

7.3 Cellcentric

7.4 Covaris Inc.

7.5 Epiontis

7.6 Epitherapeutics

7.7 Epizyme

7.8 Karus Therpeutics

7.9 Merck Millipore

7.10 Ribimed Biotechnologies

8. Appendix

Content are not available